SAFE-BioPharma Association, the nonprofit collaboration that developed and manages the global SAFE-BioPharma digital identity and digital signature standard, has elected James W. Brown, Ph.D., chief operating officer, Regenx Biosciences to its board of directors.
The SAFE-BioPharma standard is used throughout the biopharmaceutical and healthcare industries to manage digital identity trust and to apply legally binding digital signatures to electronic documents. It is a strategic initiative of the life sciences industry to facilitate secure, trusted and fully electronic business and regulatory processes. The association’s members include most of the world’s largest biopharmaceutical companies.
Based in Washington, DC, Regenx is a personalized gene therapy company focused on unmet needs of a variety of severe diseases. Before joining Regenx, Brown was responsible for IT strategy and project portfolio for R&D at MedImmune. He also worked in a variety of IT leadership roles in other life science companies. Previously, Brown was a National Research Council Postdoctoral Fellow at the National Institutes of Standards and Technology (NIST).
SAFE-BioPharma Association has an all-volunteer board which determines the association's strategic direction and business model, and oversees its management. Among numerous recent initiatives are global expansion of the standard through integration with biopharmaceutical and healthcare industry applications such as signing engines, portal providers, clinical trial applications, ePrescribing, access to eHRs and other critical digital workflows.
